BioNTechActive
The mRNA COVID-19 vaccine (BNT162b2 / tozinameran) co-developed and commercialized with Pfizer - the first mRNA vaccine authorized for human use and the product that validated the platform at global scale.
Latest update Sep 20, 2026
01
Marketed globally as an updated seasonal COVID-19 vaccine; the XFG-adapted formulation is now authorized in the EU (July 29, 2026), the US (FDA approval August 27, 2026, for adults 65+ and higher-risk 5-64 year-olds), and Canada (Health Canada authorization September 17, 2026, for ages 6 months and older, with inventory due in the coming days and weeks). Still BioNTech's primary revenue driver, but sales have collapsed faster than guided - Q2 2026 revenue was just €105.6M - driving the August 2026 guidance cut and the manufacturing-network pullback.
02
03
Announced next steps from BioNTech that mention Comirnaty.
Fall 2026
Pfizer Canada and BioNTech said September 17 that Health Canada authorized XFG-adapted COMIRNATY for ages 6 months and older and that inventory for federal and provincial programs would move through distribution channels in the coming days and weeks. Watch provincial eligibility rules and whether people outside public programs can buy the shot at participating pharmacies.
04
Pfizer Canada and BioNTech said September 17 that Health Canada authorized the XFG variant-adapted COMIRNATY vaccine for people aged 6 months and older for the 2026-2027 season. The partners said the decision rests on prior clinical, non-clinical, and real-world evidence, and Pfizer Canada said it has enough inventory for federal and provincial contracts, with distribution in the coming days and weeks. The Canadian clearance covers a broader age group than the August 27 FDA approval, which applied to adults 65 and older and higher-risk people ages 5 to 64.
05
BioNTech's flagship oncology asset: a next-generation bispecific antibody targeting both PD-L1 and VEGF-A, gained via the Biotheus acquisition and positioned as a potential immuno-oncology backbone across many solid tumors. Co-developed with Bristol Myers Squibb.
An individualized neoantigen-specific mRNA cancer vaccine, custom-manufactured for each patient's tumor mutations and co-developed with Genentech (Roche) to train the immune system against residual disease after surgery.
A HER2-targeted antibody-drug conjugate (third-generation topoisomerase-1 inhibitor payload) co-developed with China's DualityBio - BioNTech's lead candidate for its first-ever cancer-drug regulatory submission, being tested in HER2-expressing endometrial cancer and HER2-positive breast cancer.
A next-generation, topoisomerase-1-inhibitor-based antibody-drug conjugate targeting the immune-checkpoint protein B7-H3, co-developed with China's DualityBio - BioNTech's third late-stage oncology asset alongside BNT327 and trastuzumab pamirtecan, with clinical experience across more than ten tumor types.
A next-generation, pH-sensitive anti-CTLA-4 antibody designed to deplete regulatory T cells within tumors while sparing normal tissue, co-developed with OncoC4 since a March 2023 strategic collaboration ($200M upfront to OncoC4, costs and profits split on PD-(L)1 combination studies, BioNTech holding exclusive worldwide commercialization rights). It is BioNTech's fourth late-stage oncology asset alongside BNT327, trastuzumab pamirtecan, and elfetabart drozuntecan.
Investigational mRNA cancer immunotherapy encoding the HPV16 E6 and E7 proteins, also called tenu-ra. It is designed to induce HPV16-specific immune responses alongside checkpoint-inhibitor treatment. The lead study is AHEAD-MERIT (NCT04534205), a Phase 2/3 trial of BNT113 plus pembrolizumab versus pembrolizumab alone in first-line unresectable recurrent or metastatic HPV16-positive, PD-L1-expressing head and neck cancer.
06
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
Oklo
Oklo's isotope business combines the Idaho Radiochemistry Laboratory, a planned pilot reactor in Texas, and a future multi-reactor foundry to supply critical medical, industrial, research, defense, and space isotopes.
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.